The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
about
New Perspectives on Predictive Biomarkers of Tumor Response and Their Clinical Application in Preoperative Chemoradiation Therapy for Rectal CancerPrognostication and response assessment in liver and pancreatic tumors: The new imagingTargeting the NG2/CSPG4 proteoglycan retards tumour growth and angiogenesis in preclinical models of GBM and melanomaDynamic contrast enhanced MRI detects early response to adoptive NK cellular immunotherapy targeting the NG2 proteoglycan in a rat model of glioblastomaQuantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imagingImproving tumour heterogeneity MRI assessment with histograms.Imaging biomarker roadmap for cancer studiesESR statement on the stepwise development of imaging biomarkers.Translational imaging endpoints to predict treatment response to novel targeted anticancer agents.Antiangiogenic cancer therapy: monitoring with molecular US and a clinically translatable contrast agent (BR55).Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsionsMagnetic resonance perfusion imaging in neuro-oncology.Functional imaging in adult and paediatric brain tumours.Classic models for dynamic contrast-enhanced MRI.Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data.Mixed-effects modeling of clinical DCE-MRI data: application to colorectal liver metastases treated with bevacizumab.Variations of dynamic contrast-enhanced magnetic resonance imaging in evaluation of breast cancer therapy response: a multicenter data analysis challengeDynamic contrast-enhanced magnetic resonance imaging: fundamentals and application to the evaluation of the peripheral perfusionGPU-accelerated compartmental modeling analysis of DCE-MRI data from glioblastoma patients treated with bevacizumab.MRI for Assessing Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer Using DCE-MR and DW-MR Data Sets: A Preliminary ReportThe response of RIF-1 fibrosarcomas to the vascular-disrupting agent ZD6126 assessed by in vivo and ex vivo 1H magnetic resonance spectroscopy.Acute tumour response to a bispecific Ang-2-VEGF-A antibody: insights from multiparametric MRI and gene expression profiling.Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.Feasibility of using limited-population-based arterial input function for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced MRI dataCorrelation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic ratsFeasibility of using limited-population-based average R10 for pharmacokinetic modeling of osteosarcoma dynamic contrast-enhanced magnetic resonance imaging data.Dynamic Contrast Enhanced Magnetic Resonance Imaging in Oncology: Theory, Data Acquisition, Analysis, and ExamplesMultimodality multiparametric imaging of early tumor response to a novel antiangiogenic therapy based on anticalins.Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs.Automatic Segmentation of Breast Carcinomas from DCE-MRI using a Statistical Learning AlgorithmBroadening the scope of image-guided radiotherapy (IGRT).Hyperpolarized (13)C spectroscopy detects early changes in tumor vasculature and metabolism after VEGF neutralization.Evaluation of novel combined carbogen USPIO (CUSPIO) imaging biomarkers in assessing the antiangiogenic effects of cediranib (AZD2171) in rat C6 gliomas.Dynamic contrast-enhanced imaging techniques: CT and MRIMulticentre imaging measurements for oncology and in the brain.Quantification of antiangiogenic and antivascular drug activity by kinetic analysis of DCE-MRI data.False-negative MRI biomarkers of tumour response to targeted cancer therapeuticsMagnetic resonance imaging: a potential tool in assessing the addition of hyperthermia to neoadjuvant therapy in patients with locally advanced breast cancer
P2860
Q26786311-EF9C6D5A-8613-40D0-9C5C-1888A8E3BE0DQ27021568-930712CE-A966-46E4-AF28-658AD5EE154BQ27326700-D5CFC509-7AB1-4E22-9422-4C5DF17340C4Q27344690-5968751D-FA59-4D2F-8B80-AB34E5C77F8EQ27346895-46E99BD4-A1BA-4741-B169-D8ED9A73AFDEQ27693208-C6E45005-F455-400B-A94C-9403B1D839FFQ30242020-8BB57446-414E-448D-8DA7-181E51C5033CQ30456007-FDB10CF9-C4A6-48F0-A70C-9DA1C84C3055Q30465097-4297E80C-0477-4E14-95E4-83B6AF0DF671Q30474689-D86FBBA4-B0DE-4241-BF2E-D3ECBED50997Q30474759-FE169090-9F67-4B75-956C-B55483E8CE52Q30479156-91192B71-C893-43BE-B6FB-8C58AB76312FQ30577397-4043CA09-89F4-42C7-B0CE-0EFCB0AE9813Q30626277-D0EC9DC8-93AB-4215-9AFB-7DD3610F1AC2Q30651792-EE9A2AB8-4F57-4A74-9282-E07EF00C7E9DQ30653828-CB64EA9D-A2E9-4819-867E-0BAB3EF309DAQ30687678-348BA5F9-1757-4AAF-AD06-A013547206F8Q30806067-E3461A66-4E67-43E6-8C9F-EB34F0E8883BQ30810438-FC4CFFD5-367C-421A-BA19-8335B9E558AAQ30822146-06C88F12-9DCC-455E-BA17-06037887A1A1Q30912225-EF4B9081-EBB4-4E6F-8A36-D7479304831EQ30998504-9A4344F4-2DA2-4245-9A7C-8872B48D68F1Q31049713-5A7FD421-C2E7-491B-8D66-5D96A6CB6CB5Q31121875-8AEB91D0-438A-4DD0-846B-1E121E3F8FCEQ31133970-0B25687C-75BE-4918-BC2C-FAB767997A5EQ31153346-01EEF5B6-6836-4CDE-8789-3AC12B7F80FFQ33286035-A95CBFCB-83BC-480A-A9A7-376079F39596Q33417505-352389B7-86E4-4261-BDBD-F5044FB7E355Q33510695-9517EB8E-9AB7-4B67-BBA7-7A9889A272D4Q33572940-BC77051D-FB07-4A37-83AA-377C92B7A1C4Q33696408-2386B520-1C3C-4D53-9554-16EEF71897E8Q33777921-7A4FB983-805E-4DE6-A738-E6E889C05638Q33943514-7316CD25-4966-4004-B0E1-CC5AD3F1F85BQ34120237-B71F12FF-A0F1-4AC2-A2A1-4C4E900A76CAQ34145257-585EF6EB-2495-4E57-A1BE-E2DE77B977B9Q34203923-B6F0B744-3819-491B-AC80-D99A36E0A64EQ34203974-A901AA31-A020-49A8-BAF8-D83AD0D2EACDQ34269947-137D7003-BFD8-4EFC-9BD2-81D022DB2E78Q34273077-ED526D10-04E0-48D5-8198-FDA40C2B8CF9Q34390068-C0802A47-A40F-4F4A-B7D5-C22596EB4FC3
P2860
The assessment of antiangiogenic and antivascular therapies in early-stage clinical trials using magnetic resonance imaging: issues and recommendations.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The assessment of antiangiogen ...... g: issues and recommendations.
@ast
The assessment of antiangiogen ...... g: issues and recommendations.
@en
type
label
The assessment of antiangiogen ...... g: issues and recommendations.
@ast
The assessment of antiangiogen ...... g: issues and recommendations.
@en
prefLabel
The assessment of antiangiogen ...... g: issues and recommendations.
@ast
The assessment of antiangiogen ...... g: issues and recommendations.
@en
P2093
P2860
P50
P356
P1476
The assessment of antiangiogen ...... ng: issues and recommendations
@en
P2093
A R Padhani
D McIntyre
G J Rustin
I R Judson
J C Waterton
J L Evelhoch
K M Brindle
P2860
P2888
P304
P356
10.1038/SJ.BJC.6602550
P407
P50
P577
2005-05-01T00:00:00Z